Treatment for patients with myeloma has changed unrecognisably over the last two decades and now includes a sequence of treatments including chemotherapy, biological targeted therapy with or without consideration for high-dose therapy (autologous and allogeneic stem cell transplantation for younger and fit patients). As patients can now expect a doubling of median survival and a 20-30% chance of surviving longer than 10 years, the focus of treatment is shifting to long-term quality of life. This article focuses on future challenges facing clinicians treating myeloma and how best we may optimize our resources.
Introduction
It is an exciting time for those currently working in myeloma. With skilled sequential use of various treatments, it is possible to attain an ever increasingly proportion of patients with normal quality of life (QoL), living longer than 10-20 years, and for older patients this translates into 'operational cure'. [1] [2] [3] The ability of the pharmaceutical companies and regulators to fast-track development and approval of newer drugs, and the trend for worldwide collaboration coupled with patient support agencies like the Multiple Myeloma Research Foundation (MMRF) and International Myeloma Foundation (IMF) means that more clinical trials delivering new tangible treatments are available for patients with myeloma. Substantial advances have been made in our understanding of the biology of myeloma leading to the availability in the last 4 years of three new approved targeted therapies that are now in common usage, namely thalidomide, lenalidomide and bortezomib. These are being used not only in a salvage setting but also as upfront treatments in numerous trials and for non-trial patients in the clinic.
At the American Society of Haematology (ASH) meeting in December 2006, 7% of the presentations were concerning myeloma, which was the biggest single disease entity represented and most of this related to treatment. As a consequence, ASH has formed a new ad hoc Plasma Cell Biology Scientific Committee. But this means for physicians in the clinic, there are confusing messages to decide exactly how such new treatments are used in combinations, and how they fit in to the previously accepted state-of-the-art therapies of infusional chemotherapy (VAD/VAMP), highdose autologous stem cell transplantation and for some, maintenance interferon. [1] [2] [3] [4] [5] Most of all, it is not at all clear what now is the optimum treatment for relapse, and it is not possible to inform a new patient what their extended sequenced treatment plan will be.
Three areas for further progress need prioritized attention, namely:
(1) tailoring of sequential targeted treatment for an individual patient, (2) optimization of limited financial resources to best deliver treatment plans (3) how we maximize the QoL for an individual patient.
Tailoring of sequential targeted treatment for an individual patient
Difficulty in initial diagnosis and molecular methodology Early and accurate diagnosis is critical to the successful treatment of new myeloma patients, but it is difficult to diagnose early because symptoms such as fatigue, weight loss and compromised immune systems are often confused with other illnesses and specific tests relating to myeloma are not routinely done in the general practitioners surgery. As a result, patients are often misdiagnosed and/or diagnosed after preventable end-organ damage has occurred. This makes a huge difference to long term QoL. It might be timely that general physicians are educated to routinely screen for testing for paraprotein as part of the general work-up for all patients and this could be driven through the patient support groups.
With increasing use of MRI, PET, SAP scans and light chain assays, we are able to diagnose and stage patients accurately, but an understanding of the significance of which relevant genes are involved needs to be further developed to improve prognostic sub-classification. This is important because myeloma is still regarded rightly as the disease of older people and absolute numbers diagnosed and treated are increasing exponentially as life expectancy goes up and myeloma patients survive longer. A clear strategy of prolonged survival for these patients without harm is the correct vision. The issues therefore are the early accurate diagnosis with multivariate indicators of when to treat and when not to treat (including unmaintained remission), and this will lead to an increasing proportion of older patients with a normal lifespan with good QoL ('operational cure'). 2, 3 Recent methodology developments for individualized treatment strategies are the use of microfluidic chips in the application of PCR, electrophoresis sizing, cytometry, and gene-sequence detection. The signature sequence of the heavy-chain immunoglobulin VDJ sequence in myeloma is a clonotypic marker of the malignancy. An on-chip microfluidic analysis of the myeloma clonotypic sequence, combining PCR cycling on the chip and electrophoretic separation to distinguish polyclonal products of the normal population from the monoclonal 'spike' produced by the malignant clone has also been developed. [6] [7] [8] These approaches will allow analysis of unique properties of each malignant clone, detection of minimal residual disease and possibly a rapid analysis of therapeutic response.
However, these advancements in the field of molecular profiling have increased the importance of obtaining pretreatment tissue samples and subsequent samples over time that link to accessible databases of what happened to these patients clinically. Patients must be educated about the importance of providing samples. All oncologists and surgeons, including those at cancer centres and those at community practices, where most patients are evaluated, must be educated and motivated to obtain, analyse and distribute tissue samples to ensure accurate diagnosis and to enhance future research. The IMF 'Bank on a cure' programme is leading the way in this (www.myeloma.org).
Designing trials for a sequence of treatment options from diagnosis to death: the patient pathway As the result of countless trials and studies, coupled with what happens in the 'real-world clinic' outside of the context of trials, treatment packages have evolved that are being used frequently in the clinic. Examples are oral melphalan-prednisolone combinations from 1960s, the infusional VAD/CVAMP of the 1980s, and thalidomide/ dexamethasone ( þ alkylating agent) in the 1990s. More recently, there is now lenalidomide/dexamethasone ( þ alkylating agent) and the bortezomib/dexamethasone ( þ Doxil) combinations. 1, 3, [9] [10] [11] [12] [13] [14] [15] [16] [17] All of these interdigitate with high-dose melphalan, autografting, full allografting, reduced intensity conditioning allografting and interferon. 1, 4, 5, [18] [19] [20] New treatment packages do not necessarily make the old treatment obsolete, however they do pose the question: 'where do they fit in a 10-20 year sequence plan'?
Thus there are at least 10 packages of treatment that can at present be given (and more new ones each year) and some general principles are evolving in the clinics on how we sequence these treatments. For the older patients, with an expected normal lifespan of 10-20 years, the best way may be to start with a combination such as cyclophosphamide, thalidomide and dexamethasone (CTD) or melphalan, prednisolone and thalidomide (MPT) to maximum response, 21, 22 and after relapse to sequence treatment packages that each time contains only one new class of drug, for example, switching from CTD to cyclophosphamide, lenalidomide and dexamethasone. This strategy leaves in hand other classes of drugs such as proteasome inhibitors for the future, but depends upon drugs such as dexamethasone always being synergic with new previously unseen drugs. If bortezomib is combined with lenalidomide, it uses two effective classes of drugs at once (maybe without consensual benefit) and possibly reduces future options.
However with so many treatment options and with at least two new options each year there are countless possible trial permutations and combinations that could be undertaken. We therefore need to prioritize which are the most important studies to undertake that define the best sequence for therapy, and it maybe that smaller welldesigned studies answering specific questions that are not powered to give us a plethora of answers but simply take us on to the next question will be the way that we do this best.
Risk stratification approach to treatment relating to biochemical and genetic criteria or whether a 'patient is a transplant candidate or not' has been advocated by various groups and maybe the way forward in individualizing treatments, but has yet to confirmed within a prospective trials setting with mature follow-up data.
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New drugs
Various new classes of drugs currently in clinical trials include immunomodulatory drugs, proteasome inhibitors, arsenic trioxide, interleukein-1 receptor antagonists, cyclic depsipeptides, farnesyltransferase inhibitors, p38 mitogenactivated protein kinase inhibitor, modifiers of histone acetylation, heat shock protein inhibitors including KOS-953, direct AKT-targeting agents and monoclonal antibodies as well as passive and active immunotherapeutics (either given alone or in combination with established therapies). [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] The Table 1 shows some of these drugs within phase I/II studies.
The role of these new agents in relation to stem cell transplantation and their impact on the timing of transplantation (upfront versus at relapse) needs optimizing and it is this that has prompted us to produce this special issue now. A better understanding of the mechanism of action of these drugs will likely provide additional targets and insights into other potentially useful new agents. We also need to determine predictors of response to these agents based on pharmacogenomics and such studies are ongoing. Treatments with drugs like thalidomide and lenalidomide although effective are not curative, and clearly more active agents are needed if, for younger patients, the same results are to be attained as in leukaemia.
New drugs targeting bone
In myeloma bone disease, research until recently has been directed exclusively to the destructive powers of 'switched Targeted therapies for myeloma B Sirohi and R Powles on' osteoclasts. All treatment has been directed this way. We now are aware that the insidious 'switched off' osteoblast with its consequential osteopenia is equally important.
1. Bortezomib. Early phase I and II data demonstrate remarkable activity of bortezomib in combination with anthracyclines, melphalan, cyclophosphamide and thalidomide. 38, 39 Studies are also ongoing to assess the role of bortezomib on bone metabolism (NCT00128921) as there is evidence to suggest that bortezomib may increase osteoblast activity. 40 This is the only targeted therapy in use at present that is directed towards the osteoblast rather than the osteoclast. This should now be the basis of intense research for other agents.
2. Anti-receptor activator of nuclear factor-kB ligand therapy. Denosumab (formerly known as AMG 162) is a fully human monoclonal antibody directed against RANK. 41 Current phase III trials (for example, NCT00330759) are seeking approval for the use of denosumab in patients with multiple myeloma and various other cancers. Potential advantages of denosumab over the bisphosphonates is that it is completely cleared over a relatively short period of time, hence the effects on bone are not long lasting, this could be the first anti-bone-resorbing agent to stop erosions and osteolysis. [42] [43] [44] To date, the clinical experience with denosumab shows that it can effectively inhibit bone resorption with minimal side effects.
Pegylated interferon-a Data on maintenance treatment with interferon-a currently do not support its use since cost-effectiveness ratios are generally beyond acceptability. 45 This results from marginal improvements in progression-free survival without proven benefit on overall survival and an unfavourable impact of treatment on QoL. 4, 45 Use of pegylated interferon which has better patient compliance and better tolerability than interferon should be the basis for a new generation of trials with dose escalation to determine if there is a role for this form of treatment in the now long patient treatment pathway. 46 It gives the opportunity to interdigitate this novel drug between other conventional treatment packages and may lead to larger overall gains in survival, and possibly added effects relating to generalized immune stimulation. In our experience, some patients have received interferon-a for longer than 10 years with good tolerability.
Immune strategies
We have not in this special issue included a chapter on cellular immunotherapy. This is because at the moment it is purely experimental, logistically difficult, very expensive and impossible to standardize. However, this does not diminish its importance.
It is becoming clear that the human immune response is the result of highly complex continuously evolving interactions between cells of the adaptive and innate arms of the immune system, the internal and external environments, and normal and abnormal plasma cells. Immune-based strategies currently being evaluated are vaccination, including the creation of fusion cells from myeloma cells, or proteins and dendritic cells, donor lymphocyte infusions, tumor-specific T cells. [47] [48] [49] It is also speculated that immunomodulatory drugs such as lenalidomide may be useful in increasing the immune response to vaccines. We predict a huge growth in research in this area, with tangible returns in treatment options within a decade. Cost will be a very serious limitation to wide usage.
Optimization of limited financial resources to best deliver treatment plans
Cancer is becoming, for many patients, a chronic condition-incurable, but treatable, with long survival. We can expect for the near future a rapidly growing number of new treatment options, some very costly. How society determines its priorities for cancer care in relation to other major health demands and for health care versus other public expenditure is a very complex issue, but there is a growing Abbreviation: IL-6, interleukein-6.
Targeted therapies for myeloma B Sirohi and R Powles requirement that these processes should be transparent, rational and widely discussed by all stakeholders.
Health care cost delivery Introduction of these new and mostly expensive treatments poses major problems worldwide for health care systems with finite resources. Reliable assessment of efficacy and cost effectiveness of new treatments is a priority especially in comparison to standard treatments. In the United Kingdom, The National Institute of Clinical Excellence (NICE) was launched in April 1999 and covers England and Wales (www.nice.org.uk), its role being to appraise new technologies and provide guidance to NHS on clinical effectiveness and also develop guidelines outlining best practice. It has been a leader, worldwide, in how this can be done. However, there is regional inequality in implementing NICE cancer care across United Kingdom by local National Health Service (NHS) health care commissioners, increasing the development of a two-tiered system whereby patients with wealth or health insurance have access to treatments that much of the rest of the world considers standard. Also, NICE until recently has had challenges in keeping pace with the evolving field of myeloma, and United Kingdom still lags behind the United States/Europe in delivering the state-of-the-art care for patients with myeloma.
In a surprisingly new positive development, NICE has recommended that all suitable myeloma patients should be offered treatment with bortezomib. Patients showing a full or partial response to the drug should be kept on it and funded by the NHS. Patients showing a minimal or no response should be taken off the drug, and the drug costs refunded by the drug's manufacturer. Hence, patients with stable disease will have to stop the drug. The draft recommendations followed an evaluation of a refund scheme put forward by the drug's manufacturer. The final decision on whether to put the refund scheme into practice rests with the manufacturer and the Department of Health. Some argue that something is better than nothing.
Clinical versus cost effectiveness studies
Assessment of cost-effectiveness is expensive and time consuming. It is therefore essential that the decision to undertake cost-effective studies is only undertaken when it is likely to influence the subsequent use of a therapy.
Results from well-conducted randomized clinical trials with high statistical power should be the major factor in decision-making about the widespread use of expensive new agents. As clinicians caring for patients with myeloma, our primary responsibility is to advocate treatments of proven efficacy, either in terms of survival benefit or tolerability, irrespective of cost. Well-designed randomized clinical trials of adequate sample size provide the best setting to compare new with established therapies. They should, therefore, also provide the best context in which to assess comparative costs.
However, recent studies have demonstrated that results in multicentre randomized trials can vary between centres, especially when the number of patients entered at particular centres is low, and that this may have significant effect on conclusions on cost-effectiveness. In a joint study from the EORTC and MRC, the impact of treating institutions on survival of patients with poor prognosis non-seminomatous germ cell cancer treated within randomized clinical trials was studied. They reported that overall survival for patients treated in 26 institutions who entered fewer than five patients into the trial was significantly lower than in the 23 institutions where more than five patients were entered. The received dose intensity of chemotherapy was significantly lower in the low accruing centres. 50 This suggests that outcome for patients treated in low accruing institutions is worse, based on a greater tendency to reduce dose of chemotherapy, and that reliable conclusions about effectiveness (and therefore cost-effectiveness) could not be made based on data from these centres. We saw a similar 'centre effect' in bone marrow transplants for acute myeloid leukaemia, across Europe, so it is likely that myeloma behaves in a similar way. 51 Outcomes research in myeloma Outcomes in cancer are usually expressed in terms of overall survival and disease-free survival, and organizations such as the NICE have used survival data as a measure of treatment success. There is now emerging an area of research that is looking into a more global impact of all aspects of treatment benefit that can act as an end point for all parties involved in taking decisions about whether treatments have improved outcome. This includes the health care workers and patients and also the health care purchasers and facilitators such as NICE and society as a whole. Factors that now make up part of outcome research besides survival and disease-free survival are also QoL assessment, often disease-specific, and the economic implications for the individuals involved. 52 To this end, a monograph was published in the Journal of the National Cancer Institute in which the aim was to provide a review and evaluation of peer reviewed literature in cancer outcomes research. 53 The US Agency of Health Care Research and Quality and the NCI have defined outcome research as an understanding of the end results of particular health care practices and intervention, of which a key criterion is the ability to function. 54 It is clear that our understanding of current myeloma outcomes is naive and a long way from the global description above. For example, health-related QoL measurements in routine clinical practice, as distinct from its use in clinical trials, are currently rarely done. The decision-making process for care of myeloma patients will require us to pursue descriptive studies that correlate the publication of practice guidelines with the subsequent changes in patterns of care. Following this, we will need to identify which particular outcomes research findings change the decision-making process to further improve the global benefit for treatment of myeloma and in turn, this will help design better ways of undertaking myeloma outcomes research.
Outcome data from unselected patients are now expected by purchasers and presented in this way, help qualify the activity impact of advances made from research trials for the treatment of population-based cancer problems. 52 Targeted therapies for myeloma B Sirohi and R Powles
How we maximize the quality of life for individual patients
Long-term survival in myeloma/'operational cure' Because the aim of treating non-trial patients over 60 years (the majority) is to not cure the disease, but control it with normal QoL for many years, it is likely that an increasing proportion of the patients currently being treated outside of the context of research trials, are already living significantly longer than 10 years. We feel therefore that randomized trials might need to be focused not only on changes in median disease-free survival but also on increasing the proportion of patients surviving longer than 10 years. This group of patients who are operationally cured, and many of whom will die with their disease rather than of it, will best be rewarded if their QoL is maximized.
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Over the longer term, patients' QoL must be optimized. As patients with myeloma face anaemia, recurrent infections and severe bone pain, their treatment plans require continual evaluation. Furthermore, many patients also face the onset of second cancers or second and third chronic conditions related to age; and the potential long-term health consequences of treatment, including heart disease and compromised immune systems. These challenges must be taken into the treatment programme in a positive way and not an excuse to simply palliate.
Patient dilemma
QoL issues also relate to avoiding unnecessary anxiety. Once a diagnosis is confirmed, a proportion of myeloma patients are asked to 'watch and wait', putting off treatment until symptoms require intervention. These patients must learn to live with chronic cancer and manage their lives accordingly. Other patients are diagnosed with high-risk (based on various stratification systems) aggressive disease that requires immediate treatment. Both these scenarios evoke extreme anxiety and frustration as patients strive to understand the complexities of their disease. At an IMF patient-family 'interactive' seminar organized at the Royal College of Physicians, London in 2003, we examined how important Hope and Trust was for the patients and their carers. We asked a total of 52 questions relating to health care workers, the environment and the treatment and its responses (www.myeloma.org). In no instance, was the response to a question unanimous and unambiguous in its answer, and thus the immediate take home message of the meeting was that it is impossible to proscribe recommendations for all patients that will not often be inappropriate to a minority. For example, we asked patients that had entered a trial and were randomized between treatment options-'did this erode your Hope and Trust' and 9% said yes. Concerning the doctor, 87% felt that if the doctor was upbeat and positive, this would increase Trust but 13% thought otherwise. Another intriguing observation was that in the United Kingdom, we found only 2% of patients recorded their consultation with doctors in contrast to the United States where about 50% patients would record the interview.
Although support via Internet and patient helpline through agencies such as the MMRF, IMF is available, clinicians generally handle this on an ad hoc basis with little professional input. What influences 'Hope and Trust' by patients is very individually driven.
The emergence of new drugs and trials in haematological malignancies brings hope to patients; however, understanding the advantages and accessibility of new and emerging treatments can be overwhelming. Although many patients rely on their community oncologist for guidance, the community oncologist may not be up-to-date on the latest approaches for myeloma. Easy access to up-to-date information about treatment options is critical to ensure that appropriate medical decisions are made.
Random searching of the Internet is not appropriate, and the patient support groups such as the IMF, MMRF and the UKMF seem to be competing with each other rather than complimenting. It may be time all of these agencies met and put their resources together. The European Myeloma Network (www.myeloma-europe.org) was initiated in 2003 in order to allow scientists and physicians with interest in Multiple Myeloma and related disorders to share their experience and develop co-operative studies, but at present it is not widely used by clinicians.
Bone disease/vertebroplasty: increasing awareness Bone destruction at any site is the cause of significant morbidity in patients with myeloma. 55 Patients can for example present with a pathological fracture of a long bone, rib or the sternum, but easily the most upsetting and potentially dangerous site is the spine. Besides the direct clinical implications, a source of huge distress is the loss of up to 10 cm in height because of vertebral collapse, which may continue to occur during the initial period after the start of treatment, and therefore the speed of response may be a factor in the final total loss of height. There therefore arises the possibility that for certain selected patients, rapid response may be crucial to their long-term QoL. Again, we need evidence-based methodology to define which specific treatment is best for an individual patient. This clearly needs to be linked to radiotherapy and vertebroplasty/ balloon kyphoplasty, but at present there are no randomized studies to define the place of radiotherapy in this context, and the possibility exists that radiotherapy could for some patients lead to increased height loss if given early after diagnosis because it inhibits osteoblast activity but drugs like bortezomib which promotes osteoblast activity laying down new bone early may reduce vertebral collapse. 40 Advances in minimally invasive surgical techniques, such as percutaneous vertebroplasty or balloon kyphoplasty, offer these patients' less-invasive options for treating vertebral collapse and restoring function. 55 However, undertaking randomized trials of vertebroplasty would be a logistic and ethical nightmare, and would require prolonged follow-up to determine long-term significance. The IMF is currently looking at current physician practice data, which at least gives us a feel for how this practice is evolving outside of the context of clinical trials.
Vertebroplasty has impacted significantly on patient's QoL along with the use of oral and i.v. bisphosphonates. Biophosphonates are considered cost effective and have become part of routine practice since they significantly improve QoL by preventing skeletal events. 56 However, they are costly and no data are available to assess correctly the cost per quality adjusted life years (QALY) associated with these treatments. There is no evidence to support the choice of either pamidronate or zoledronic acid based on cost-effective parameters. 57 However, due to its practical benefit of shorter infusion time zoledronic acid is anticipated to have QoL benefits and economic benefits and is therefore probably the more preferred option in clinical practice in Europe. There is an urgent need for bone density assessment studies, particularly for patients in remission to optimize when bisphosphonate treatment can be stopped.
Osteonecrosis of jaw has emerged as a bizarre and completely unexpected adverse effect of long-term bisphosphonate therapy that could not have been predicted from any phase II studies. Physicians need to be aware of this potentially serious complication, and should practice vigilant monitoring of myeloma patients who are currently receiving any form of bisphosphonate therapy. 58 However, the harmful consequences of not controlling demineralization of bone far outweigh this easily preventable side effect.
Charities and information systems Independent charities like MMRF, IMF and UKMF now are the driving force worldwide to helping patients for all aspects of their disease including setting the agenda for relevant research. Government funding to boost these bodies, which have organized consensus guidelines and initiated and nurtured research into myeloma, should be encouraged. Each of these bodies has a panel of experts acting as scientific advisors, and also has the unanimous support of all health care workers.
Concluding remarks
This special issue has attempted to look at the place of modern targeted therapy, transplantation and support that has followed the extraordinary developments in myeloma that occurred after the introduction of high-dose melphalan 25 years ago. 59 There have been developments and delivery of service that would have been undreamt of 10 years ago. We hope that we have highlighted the relevant developments that mean most to the patients at present and those for the foreseeable future. We do realize however, the biggest challenge for the next decade will be coordinating this in a background of increasingly severe financial restraints. It is possible that the newer targeted drugs may obviate the need for high-dose therapy in the future.
